All In Biotech

Drug Trial Radar · NCT00731679

Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS)

A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin 550 mg TID in the Treatment of Subjects With Non-Constipation Irritable Bowel Syndrome

Last checked: Nov 20, 2026Latest source record: Nov 29, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 623 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

623

Actual

Start

Jul 2008

Primary completion

Aug 2009

Study completion Sep 2009

Sponsor

Lead sponsor
Bausch Health Americas, Inc.Industry
Sponsor type
Industry
First posted
Aug 11, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the efficacy of a 14-day course of rifaximin given 3 times a day vs. placebo in providing adequate relief of IBS symptoms.

Conditions

  • Non-Constipation Irritable Bowel Syndrome

Interventions

  • RifaximinDrug

  • PlaceboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Subjects Who Had Adequate Relief of Global IBS Symptoms for at Least 2 of the 4 Weeks During the Primary Evaluation Period (ie, Weeks 3 Through 6).Time frame: 4 weeks

Locations

96 sites in 2 countries. Site status is shown where the registry gives one.

  • Site not named

    Hueytown, Alabama

  • Site not named

    Phoenix, Arizona

  • Site not named

    Sierra Vista, Arizona

  • Site not named

    Tucson, Arizona

  • Site not named

    Little Rock, Arkansas

  • Site not named

    Little Rock, Arkansas

  • Site not named

    Sherwood, Arkansas

  • Site not named

    Anaheim, California

  • Site not named

    Lancaster, California

  • Site not named

    Los Angeles, California

  • Site not named

    Murrieta, California

  • Site not named

    San Diego, California

  • Site not named

    Lakewood, Colorado

  • Site not named

    Bridgeport, Connecticut

  • Site not named

    Torrington, Connecticut

  • Site not named

    Altamonte Springs, Florida

  • Site not named

    Boynton Beach, Florida

  • Site not named

    Gainesville, Florida

  • Site not named

    Hollywood, Florida

  • Site not named

    Jupiter, Florida

  • Site not named

    Lauderdale Lakes, Florida

  • Site not named

    Maitland, Florida

  • Site not named

    Naples, Florida

  • Site not named

    New Port Richey, Florida

  • Site not named

    Orlando, Florida

  • Site not named

    West Palm Beach, Florida

  • Site not named

    Winter Garden, Florida

  • Site not named

    Winter Park, Florida

  • Site not named

    Topeka, Kansas

  • Site not named

    Shreveport, Louisiana

  • Site not named

    Baltimore, Maryland

  • Site not named

    Hagerstown, Maryland

  • Site not named

    Silver Spring, Maryland

  • Site not named

    Boston, Massachusetts

  • Site not named

    Detroit, Michigan

  • Site not named

    Kalamazoo, Michigan

  • Site not named

    Paw Paw, Michigan

  • Site not named

    Jackson, Mississippi

  • Site not named

    St Louis, Missouri

  • Site not named

    Lebanon, New Hampshire

Showing 40 of 96 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.